无症状型甲状旁腺功能亢进症的诊治进展

doi:10.3969/j.issn.1004-583X.2022.07.013

摘要/Abstract

摘要：

无症状型甲状旁腺功能亢进症(asymptomatic primary hyperparathyroidism, aPHPT)在欧美国家十分常见, 在我国的占比也逐年增多。aPHPT主要通过血钙筛查和颈部超声被意外检出, 其定义比较紊乱, 对于“无症状”具有不同的表述, 共同的特点是虽然没有明确的临床症状和体征, 但靶器官的受累还是存在的, 疾病处于隐匿进展中。aPHPT定义需要被明确, 也需要更好地进行分类管理。目前手术是aPHPT唯一的根治方法, 可以消除疾病进展的潜在风险。但对于靶器官受累不明确的患者手术获益能否超过其风险需要被进一步评估, 需要更多前瞻性随机对照试验来提供证据。

中图分类号:

R582.1

钟鸣, 李伟. 无症状型甲状旁腺功能亢进症的诊治进展[J]. 临床荟萃, 2022, 37(7): 648-652.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2022.07.013

https://huicui.hebmu.edu.cn/CN/Y2022/V37/I7/648

图/表 1

参考文献 48

[1]	中华医学会骨质疏松和骨矿盐疾病分会. 原发性甲状旁腺功能亢进症诊疗指南[J]. 中华骨质疏松和骨矿盐疾病杂志, 2014, 7(3): 187-198.
[2]	Walker MD, Silverberg SJ. Primary hyperparathyroidism[J]. Nat Rev Endocrinol, 2018, 14(2):115-125. doi: 10.1038/nrendo.2017.104 pmid: 28885621
[3]	Zhao L, Liu JM, He XY, et al. The changing clinical patterns of primary hyperparathyroidism in Chinese patients: Data from 2000 to 2010 in a single clinical center[J]. J Clin Endocrinol Metab, 2013, 98(2):721-728. doi: 10.1210/jc.2012-2914 pmid: 23365127
[4]	Lin X, Fan Y, Zhang Z, et al. Clinical characteristics of primary hyperparathyroidism: 15-year experience of 457 patients in a single center in China[J]. Front Endocrinol (Lausanne), 2021, 12:602221. doi: 10.3389/fendo.2021.602221 URL
[5]	Liu Y, Guo S, Wu J, et al. Changes in clinical patterns of Chinese patients with primary hyperparathyroidism in the past 12 years:A single-center experience[J]. Endocr Connect, 2021, 10(11):1428-1434. doi: 10.1530/EC-21-0382 URL
[6]	闫双通, 田慧, 李春霖, 等. 中老年人群原发性甲状旁腺功能亢进症患病率初步调查[J]. 中华内科杂志, 2007, 46(8):651-653.
[7]	邵建平, 孙展展, 杜斯娜, 等. 成人高血钙患者中筛查高钙型原发性甲状旁腺功能亢进症结果分析[J]. 现代实用医学, 2015, 27(1):57-58.
[8]	李楠, 罗斌. 北京某医院高钙血症的流行病学调查[J]. 北京医学, 2020, 42(3):214-217.
[9]	Bilezikian JP, Brandi ML, Eastell R, et al. Guidelines for the management of asymptomatic primary hyperparathyroidism: Summary statement from the Fourth International Workshop[J]. J Clin Endocrinol Metab, 2014, 99(10):3561-3569. doi: 10.1210/jc.2014-1413 pmid: 25162665
[10]	Bilezikian JP, Potts JT Jr, Fuleihan Gel-H, et al. Summary statement from a workshop on asymptomatic primary hyperparathyroidism: A perspective for the 21st century[J]. J Clin Endocrinol Metab, 2002, 87(12):5353-5361. doi: 10.1210/jc.2002-021370 URL
[11]	廖二元, 袁凌青. 内分泌代谢学[C]. 第4版上册. 北京: 人民卫生出版社, 2019: 503.
[12]	满娜, 曾正陪. 中华医学会内分泌学分会代谢综合征与亚临床内分泌代谢疾病研讨会纪要[J]. 中华内科杂志, 2008, 47(3):245-247.
[13]	Castellano E, Tassone F, Attanasio R, et al. Mild primary hyperparathyroidism as defined in the Italian Society of Endocrinology's Consensus Statement: Prevalence and clinical features[J]. J Endocrinol Invest, 2016, 39(3):349-354. doi: 10.1007/s40618-015-0412-6 pmid: 26620949
[14]	Rubin MR, Bilezikian JP, McMahon DJ, et al. The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years[J]. J Clin Endocrinol Metab, 2008, 93(9):3462-3470. doi: 10.1210/jc.2007-1215 URL
[15]	Lundstam K, Heck A, Godang K, et al. Effect of surgery versus observation: Skeletal 5-year outcomes in a randomized trial of patients with primary HPT (the SIPH Study)[J]. J Bone Miner Res, 2017, 32(9):1907-1914. doi: 10.1002/jbmr.3177 pmid: 28543873
[16]	Cipriani C, Biamonte F, Costa AG, et al. Prevalence of kidney stones and vertebral fractures in primary hyperparathyroidism using imaging technology[J]. J Clin Endocrinol Metab, 2015, 100(4):1309-1315. doi: 10.1210/jc.2014-3708 pmid: 25646791
[17]	Tay YD, Liu M, Bandeira L, et al. Occult urolithiasis in asymptomatic primary hyperparathyroidism[J]. Endocr Res, 2018, 43(2):106-115. doi: 10.1080/07435800.2018.1431275 URL
[18]	张鹏. 肾结石患者尿钙、镁、钠、钾与尿阳离子的相关性分析[J]. 医学信息, 2021, 34(18):110-112.
[19]	Bollerslev J, Jansson S, Mollerup CL, et al. Medical observation, compared with parathyroidectomy, for asymptomatic primary hyperparathyroidism: A prospective, randomized trial[J]. J Clin Endocrinol Metab, 2007, 92(5):1687-1692. doi: 10.1210/jc.2006-1836 URL
[20]	郭欣, 郭珲. PHPT对肾功能影响的临床和分子研究进展[J]. 西南国防医药, 2020, 30(12):1136-1139.
[21]	Silverberg SJ, Clarke BL, Peacock M, et al. Current issues in the presentation of asymptomatic primary hyperparathyroidism:Proceedings of the Fourth International Workshop[J]. J Clin Endocrinol Metab, 2014, 99(10):3580-3594. doi: 10.1210/jc.2014-1415 pmid: 25162667
[22]	Beysel S, Caliskan M, Kizilgul M, et al. Parathyroidectomy improves cardiovascular risk factors in normocalcemic and hypercalcemic primary hyperparathyroidism[J]. BMC Cardiovasc Disord, 2019, 19(1):106. doi: 10.1186/s12872-019-1093-4 URL
[23]	Tournis S, Makris K, Cavalier E, et al. Cardiovascular risk in patients with primary hyperparathyroidism[J]. Curr Pharm Des, 2020, 26(43):5628-5636. doi: 10.2174/1381612824999201105165642 URL
[24]	Bilezikian JP, Bandeira L, Khan A, et al. Hyperparathyroidism[J]. Lancet, 2018, 391(10116):168-178. doi: S0140-6736(17)31430-7 pmid: 28923463
[25]	Anagnostis P, Vaitsi K, Veneti S, et al. Efficacy of parathyroidectomy compared with active surveillance in patients with mild asymptomatic primary hyperparathyroidism: A systematic review and meta-analysis of randomized-controlled studies[J]. J Endocrinol Invest, 2021, 44(6):1127-1137. doi: 10.1007/s40618-020-01447-7 pmid: 33074457
[26]	Seib CD, Ganesan C, Arnow KD, et al. Association of parathyroidectomy with 5-year clinically significant kidney stone events in patients with primary hyperparathyroidism[J]. Endocr Pract, 2021, 27(9):948-955. doi: 10.1016/j.eprac.2021.06.004 pmid: 34126246
[27]	Huang SY, Burchette R, Chung J, et al. Parathyroidectomy for nephrolithiasis in primary hyperparathyroidism: Beneficial but not a panacea[J]. Surgery, 2022, 171(1):29-34. doi: 10.1016/j.surg.2021.03.077 URL
[28]	Tassone F, Guarnieri A, Castellano E, et al. Parathyroidectomy halts the deterioration of renal function in primary hyperparathyroidism[J]. J Clin Endocrinol Metab, 2015, 100(8):3069-3073. doi: 10.1210/jc.2015-2132 pmid: 26079781
[29]	Matzen J, Bislev LS, Sikjær T, et al. The effect of parathyroidectomy compared to non-surgical surveillance on kidney function in primary hyperparathyroidism: A nationwide historic cohort study[J]. BMC Endocr Disord, 2022, 22(1):14. doi: 10.1186/s12902-021-00918-z pmid: 34991581
[30]	朱旻婷, 刘建民. 原发性甲状旁腺功能亢进症神经心理改变及可能机制[J]. 中华骨质疏松和骨矿盐疾病杂志, 2018, 11(5):503-508.
[31]	Tournis S, Makris K, Cavalier E, et al. Cardiovascular risk in patients with primary hyperparathyroidism[J]. Curr Pharm Des, 2020, 26(43):5628-5636. doi: 10.2174/1381612824999201105165642 URL
[32]	Wilhelm SM, Wang TS, Ruan DT, et al. The American Association of Endocrine Surgeons Guidelines for definitive management of primary hyperparathyroidism[J]. JAMA Surg, 2016, 151(10):959-968. doi: 10.1001/jamasurg.2016.2310 pmid: 27532368
[33]	Marcocci C, Brandi ML, Scillitani A, et al. Italian Society of Endocrinology Consensus Statement: Definition, evaluation and management of patients with mild primary hyperparathyroidism[J]. J Endocrinol Invest, 2015, 38(5):577-593. doi: 10.1007/s40618-015-0261-3 pmid: 25820553
[34]	Singh Ospina N, Maraka S, Rodriguez-Gutierrez R, et al. Comparative efficacy of parathyroidectomy and active surveillance in patients with mild primary hyperparathyroidism: A systematic review and meta-analysis[J]. Osteoporos Int, 2016, 27(12):3395-3407. pmid: 27562567
[35]	Anagnostis P, Vaitsi K, Veneti S, et al. Efficacy of parathyroidectomy compared with active surveillance in patients with mild asymptomatic primary hyperparathyroidism: A systematic review and meta-analysis of randomized-controlled studies[J]. J Endocrinol Invest, 2021, 44(6):1127-1137. doi: 10.1007/s40618-020-01447-7 pmid: 33074457
[36]	Liu F, Yu X, Liu Z, et al. Comparison of ultrasound-guided percutaneous microwave ablation and parathyroidectomy for primary hyperparathyroidism[J]. Int J Hyperthermia, 2019, 36(1):835-840.
[37]	白求恩精神研究会内分泌和糖尿病学分会介入内分泌专业委员会学组, 中国健康促进基金会骨代谢疾病防治专项基金管委会. 原发性甲状旁腺功能亢进热消融治疗专家共识(2021版)[J]. 中日友好医院学报, 2021, 35(5):259-264.
[38]	Wu W, Zhou Q, Xu S, et al. Two-year changes of biochemical profiles and bone mineral density after percutaneous ultrasound-guided microwave ablation for primary hyperparathyroidism[J]. Endocrine, 2021, 71(2):476-483. doi: 10.1007/s12020-020-02511-1 pmid: 33025562
[39]	Ni W, Yuan Y, Chu X, et al. Bone turnover markers in response to ultrasound-guided microwave ablation for primary hyperparathyroidism[J]. Front Endocrinol (Lausanne), 2021, 12:782050. doi: 10.3389/fendo.2021.782050 URL
[40]	Wei Y, Peng CZ, Wang SR, et al. Microwave ablation versus radiofrequency ablation for primary hyperparathyroidism: A multicenter retrospective study[J]. Int J Hyperthermia, 2021; 38(1):1023-1030. doi: 10.1080/02656736.2021.1945689 URL
[41]	Wei Y, Peng L, Li Y, Zhao ZL, et al. Clinical study on safety and efficacy of microwave ablation for primary hyperparathyroidism[J]. Korean J Radiol, 2020, 21(5):572-581. doi: 10.3348/kjr.2019.0593 pmid: 32323502
[42]	Liu Y, Peng C, Chai H, et al. Predicting ultrasound-guided thermal ablation benefit in primary hyperparathyroidism[J]. Eur Radiol, 2022.
[43]	Marcocci C, Bollerslev J, Khan AA, et al. Medical management of primary hyperparathyroidism: Proceedings of the fourth International Workshop on the Management of asymptomatic primary hyperparathyroidism[J]. J Clin Endocrinol Metab, 2014, 99(10):3607-3618. doi: 10.1210/jc.2014-1417 pmid: 25162668
[44]	Bilezikian JP. Primary hyperparathyroidism[J]. J Clin Endocrinol Metab, 2018, 103(11):3993-4004. doi: 10.1210/jc.2018-01225 pmid: 30060226
[45]	Cipriani C, Nemeth EF, Bilezikian JP. Drugs acting on the calcium receptor: Calcimimetics and calcilytics[M]. Academic Press, 2020: 1657-1670.
[46]	Miyaoka D, Imanishi Y, Kato E, et al. Effects of denosumab as compared with parathyroidectomy regarding calcium, renal, and bone involvement in osteoporotic patients with primary hyperparathyroidism[J]. Endocrine, 2020, 69(3):642-649. doi: 10.1007/s12020-020-02401-6 pmid: 32621048
[47]	周悦玲, 丁峰, 李雪竹. 泌尿系结石的成石机制及药物治疗[J]. 上海医药, 2019, 40(17):3-6, 36.
[48]	吕建林. 枸橼酸氢钾钠防治泌尿系结石的研究进展[J]. 实用临床医药杂志, 2020, 24(21):118-123.

无症状型甲状旁腺功能亢进症的诊治进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 1

参考文献 48

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王奕涵, 秦旭雁, 韩宣泽, 王樱洁, 高菲菲, 陈春红, 张岭楠, 张芳. 利伐沙班用于HASBLED评分≥3分的高龄非瓣膜性心房颤动患者的有效性和安全性[J]. 临床荟萃, 2024, 39(2): 121-124.
[2]	金鑫, 吴金玲, 尹丽丽. 持续性植物状态促醒机制及治疗研究进展[J]. 临床荟萃, 2024, 39(2): 172-176.
[3]	王琦, 陈宏. 维生素D在支气管哮喘和慢性阻塞性肺疾病治疗中的应用进展[J]. 临床荟萃, 2024, 39(1): 88-91.
[4]	崔兰丹, 杨春燕. 脓毒症患者甲状腺激素的变化特点及研究进展[J]. 临床荟萃, 2024, 39(1): 70-74.
[5]	邹子良, 余海, 王迪, 褚泰运, 李驹, 钱宝堂. 冠状动脉慢性完全闭塞病变介入治疗研究现状[J]. 临床荟萃, 2024, 39(1): 80-83.
[6]	游琪琪, 霍丽娟. 原发性胆汁性胆管炎-自身免疫性肝炎重叠综合征的诊治进展[J]. 临床荟萃, 2024, 39(1): 84-87.
[7]	赵浩天, 李丽. 肺超声在心脏急重症疾病合并肺水肿中应用的研究进展[J]. 临床荟萃, 2023, 38(9): 832-837.
[8]	王鑫, 张展, 刘铎, 谢萍. 铁缺乏与肺动脉高压相关性的研究进展[J]. 临床荟萃, 2023, 38(9): 838-844.
[9]	陈聪水, 李园, 陈淑芳. 重视儿童胆源性胰腺炎的中西医诊治(附1例分析)[J]. 临床荟萃, 2023, 38(8): 726-730.
[10]	武锐锋, 刘宇宏. PDZ结合激酶/T淋巴细胞因子激活的杀伤细胞源性蛋白激酶的作用机制及其在肿瘤治疗中的潜在价值[J]. 临床荟萃, 2023, 38(8): 763-768.
[11]	侯有玲, 李奕, 关红玉, 罗红霞. 目标导向液体治疗在脑肿瘤切除术中应用效果的meta分析[J]. 临床荟萃, 2023, 38(8): 686-693.
[12]	王玥, 陈辉, 岑奕, 张哲, 张欣, 李宗锡, 陈珍珍, 贾彤彤, 章美玲. 超声引导下侧入路颈脊神经后支三氧联合注射松解治疗颈脊神经后支源性慢性颈肩痛[J]. 临床荟萃, 2023, 38(8): 714-718.
[13]	张会, 丁东瑞, 金天然. 新型冠状病毒SARS-CoV-2的相关研究——过去与未来[J]. 临床荟萃, 2023, 38(7): 638-646.
[14]	郭文惠, 雷皓月, 潘友卓, 张琦. 质膜膜泡关联蛋白的生物学功能研究进展[J]. 临床荟萃, 2023, 38(7): 647-653.
[15]	陈瑾, 吕鸿雁, 刘晗, 刘建宁, 卢佳配, 张金巧. 靶向BCMA的嵌合抗原受体T细胞治疗三重难治性多发性骨髓瘤的研究进展[J]. 临床荟萃, 2023, 38(7): 654-658.